Form 4 for CLDX Celldex Therapeutics, Inc.
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-02 · accession 0001709024-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-06 | 2026-01-02 | CLDX | Martin Samuel Bates | SVP AND CFO | M - OptEx | $10.38 | +4,817 | 32.9K | +17% | +$50.0K |
| D | 2026-01-06 | 2026-01-02 | CLDX | Martin Samuel Bates | SVP AND CFO | M - OptEx | $0.00 | -4,817 | 58.8K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | M | A | 4,817 | $10.38 | 32,942 | D | — | — | |
| 2 | Derivative | Incentive Stock Option (Right to Buy) | 2026-01-02 | M | D | 4,817 | $0.00 | 58,815 | D | $10.38 · — to 2030-06-18 | 4,817 Common Stock | (F1) As of June 18, 2024, the option is fully vested. |